THE PLACE OF ENZALUTAMIDE IN THE SERIAL TREATMENT OF TREATMENT-RESISTANT PROSTATE CANCER

Prostate cancer initially responds to androgen-deprivation therapy, but most patients eventually develop a castration-resistant form of disease. Enzalutamid is the superselective inhibitor of the androgen receptor (AR), which blocks several stages of the AR signal path. The drug showed significant e...

Full description

Saved in:
Bibliographic Details
Main Authors: A. A. GRITSKEVICH, S. V. MISHUGIN, I. G. RUSAKOV
Format: Artigo
Language:Russo
Published: Remedium Group LLC 2017-06-01
Series:Медицинский совет
Subjects:
metastatic cancer
enzalutamide
abiraterone acetate
castration resistance
Online Access:https://www.med-sovet.pro/jour/article/view/1894
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items